Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06239532 | HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma | PHASE2 | ACTIVE NOT_RECRUITING | 28 | — | — | Sep 27, 2022 | Dec 31, 2025 | Nov 21, 2024 | 1 | China |
the sum of complete response rate and partial response rate
| Arm | Type | Description |
|---|---|---|
| TAE+HAIC+Tislelizumab+Surufatinib | EXPERIMENTAL | Patients will receive hepatic arterial infusion chemotherapy (HAIC) sequential transcatheter arterial embolization(TAE) combined with Tislelizumab and Surufatinib |
| Name | Type | Description |
|---|---|---|
| HAIC+TAE | DRUG | Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days. |
| Tislelizumab | DRUG | Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks |
| Surufatinib | DRUG | Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time. |
Inclusion Criteria: 1. Written informed consent for the trial. 2. Aged ≥18 years. 3. Histologically confirmed intrahepatic cholangiocarcinoma. 4. No other previous systematic treatment for BTC. 5. At least one measurable lesion (RECIST 1.1). 6. Eastern Cooperative Oncology Group performance status ...